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The objective of this study was to determine the effects of in ovo injection of nicotinamide 
riboside (NR) on avian embryonic myogenesis. In experiment one, fertilized broiler eggs 
(n=156; Cobb 500) were randomly assigned to 1 of 4 treatments in a completely randomized 
design with a 2 × 2 factorial arrangement. Factor 1 consisted of treatment (TRT), with 
eggs injected with 100 µl of 0.0 (-) or 2.5 mM (+) NR in sterile saline. Factor 2 was injection 
location (LOC), with either treatment injected into the yolk (YO) or albumin (AL). Post-hatch, 
chicks were euthanized and body and pectoralis major (PM) measures were examined. The left 
PM was kept for muscle fiber analysis. There were no TRT×LOC interactions for all body and 
PM measures (P ≥ 0.07), except PM weight and length (P < 0.01). Pectoralis major muscles 
from the YO+ treatment were heavier (P < 0.01) than all other treatments. Length of PM from 
AL+ were longer than control chicks injected into either the yolk or albumen (P < 0.04), but was 
shorter (P < 0.01) than YO+ chicks. There was a TRT×LOC interaction for muscle fibers per 
1000m2 with YO+ muscles having the largest number of fibers (P < 0.01) compared to all other 
treatments, which did not differ (P ≥ 0.16) from each other.  There were no TRT×LOC (P ≥ 
0.43) interactions for muscle fiber cross sectional area. Injected NR increased PM muscle 
development and greater effects were seen when NR is injected into the yolk. In experiment two, 
the effect of increasing in ovo NR concentration on avian myogenesis was examined. 
Fertilized broiler eggs (n=420; Cobb 500) were randomly assigned to 1 of 4 treatments:  0.0, 2.5, 
5.0, or 10.0 mM NR made in 0.9% sterile saline. At d10 of incubation, 100l of allotted 
treatment was injected only into the egg yolk. After euthanasia, body measures, PM measures, 
leg area, and muscle fiber characteristics were analyzed for broiler chicks. For d21 chicks, there 
were no treatment differences for body measures (P≥0.08), excluding head length and chest 
  
width, which were larger (P≥0.05) from 2.5mM NR compared to the saline treatment. The 
weight and width of chick PM were increased (P<0.01) at every NR level. Chicks given 2.5 and 
5mM NR solutions had longer PM measurements (P≤0.01) than saline chicks. Injection of 5mM 
NR increased PM depth (P≤0.04) from d21 chicks. Treatment did not affect leg muscle area or 
muscle fiber CSA (P≥0.20). All NR injections increased muscle fiber number (P<0.01); though 
10mM injection led to the largest increase in fibers (P<0.01). Injecting up to 5.0 mM NR in the 
yolk of the developing embryo did not affect body weight but increased PM measures, indicating 
NR influenced avian myogenesis. Key Words: broiler, in ovo injection, nicotinamide riboside, 
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Chapter 1 - Introduction 
Food security, or the state of having access to sufficient, affordable, nutritious food, has 
become a crucial topic for scientists around the world. With the world population increasing 
from 7.5 billion in 2018 to a projected 9.4 billion in 2050 (U.S. Census Bureau, 2018), providing 
enough food for the world’s inhabitants is critical. 
In the United States, meat from beef, pork, and poultry is the number one source of 
protein for the vast majority of people (Phillips et al., 2015). One focus of the agricultural 
industry is to meet the demands of the growing population for meat as a protein. Consumers 
preferences for meat have changed in past years. Historically, per capita consumption of red 
meats had more than doubled chicken consumption; however, in 1993, chicken consumption had 
overtaken both pork and beef. In the past 60 years, per capita consumption of chicken has 
increased by 229% (USDA, 2018). With chicken consumption in the U.S. continually on the rise, 
researchers are investigating ways to maximize the availability of this protein.  
Several methods could be utilized to meet the demands of the consumers: increasing 
production of broilers, increasing growth rate of broilers, or increasing the amount of muscle 
found on each broiler. To achieve improved growth rate or muscle accumulation, one potential 
approach could be to alter myogenesis during development of broilers. Myogenesis is the 
formation of muscle and occurs during development of the broiler in the egg. Overall muscle 
mass is determined by gestational hyperplasia, and increase in muscle fiber number, and 
postnatal hypertrophy, an increase in fiber size (Lawrence et al., 2012). To increase the quantity 
of meat harvested from broilers, either fiber number or fiber size within the skeletal muscle must 
be altered. 
 2 
Nicotinamide riboside (NR), a vitamin B3 analogue and NAD+ precursor (Chi and 
Sauve, 2013), has positive effects on skeletal muscle qualities in mice. Canto et al. (2013), found 
NR increased NAD+ levels in muscle mitochondria. In skeletal muscle, NAD+ acts as an electron 
transfer molecule and plays a role in energy production (Nelson and Cox, 2007).  Increasing 
levels of NAD+ via NR supplementation may shield skeletal muscle from decline due to aging in 
mice (Guarente et al., 2016; Fletcher et al., 2017). Nicotinamide riboside has not only shown to 
increase NAD+ levels in the muscle mitochondria, it also has increased mitochondrial biogenesis 
in mice as well (Khan et al., 2014). Mitochondria has many critical roles in skeletal muscle, 
including energy provision and cellular metabolism. With an increase in mitochondria due to NR 
supplementation, ATP production is also amplified (Khan et al., 2014; Ryu et al., 2016; 
Frederick et al., 2016; Zhang et al., 2016). Though results have not been consistent in all studies, 
some experiments show positive influences on both skeletal muscle growth as well as muscle 
fiber characteristics (Khan et al., 2014; Frederick et al., 2016; Ryu et al, 2016). Due to the 
changes made to the skeletal muscle physiology, altered muscle performance and endurance has 
been observed (Canto et al., 2012; Frederick et al., 2016; Kourtzidis et al., 2016; Ryu et al., 
2016; Zhang et al., 2016). 
Administration of NR has varied among studies. For the majority, supplementation has 
occurred via oral dosage in either feed or water supply (Canto et al., 2013; Khan et al., 2014; 
Guarente et al., 2016; Fletcher et al., 2017). One potential technique to deliver NR to growing 
broiler embryos, is to inject supplementation into the egg. While previous studies have used in 
ovo injection of other supplements such as amino acids, carbohydrates, hormones, probiotics, 
and immunostimulants (Roto et al., 2016), no study has utilized in ovo injection of NR.  
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While there are many studies examining the effects of NR supplementation on skeletal 
muscle in mice, none have been observed in broilers. Therefore, the objective of this study was 
to observe the effects of in ovo injection of nicotinamide riboside on whole-body growth 
measurements, NAD+ content, mitochondrial quantity, and myogenesis in broilers. 
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Chapter 2 - General review of literature 
 BROILER EMBRYONIC MYOGENESIS 
 Origin of skeletal muscle 
Skeletal muscle is vital for both movement and support of the body. Myogenesis is the 
creation and formation of skeletal muscle, which only occurs during embryo development. 
During the embryonic phase of development, skeletal muscle originates from the mesoderm, one 
of three layers of the trilaminar disk that forms during gastrulation which occurs. The mesoderm 
later differentiates into muscle, bone, and some organs. As part of gastrulation, somitogenesis 
occurs where somites are initially formed. Somites are cuboidal, fluid filled clusters of 
mesoderm stem cells that form along the neurotube of the embryo and have a predetermined 
outcome. From the somites, after activation with the myogenic factor Myf5, myogenesis 
transpires.  
Myogenesis occurs in two waves. The timing of myogenesis is different for each species. 
In poultry, primary myogenesis initiates from Pax3+ and Pax7+ progenitor cells, or muscle stem 
cells. This first waves forms primary myofibers, which act as a foundation where additional 
muscle fibers will later be established. This takes place between days 3 and 7 of development of 
a broiler embryo (Chal and Pourquie, 2017).  Secondary myogenesis, or the second wave of 
muscle formation, then adds more myofibers around the primary fibers. This wave starts after 
primary myogenesis has ended, beginning at day 8 of embryogenesis (Chal and Pourquie, 2017). 
These primary and secondary fibers fuse together to create muscle bundles, which together 
establish muscle. Pax7+ progenitor cells will produce adult muscle stem cells, also known as 
satellite cells, which are capable of repairing damaged muscle later on.  
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During myogenesis, hyperplasia is occurring, which is the proliferation of muscle cells. 
An increase in muscle fibers only occur at this point in time, during myogenesis of a growing 
embryo. Once myogenesis is complete and after the animal is born, expansion of muscle relies 
on only hypertrophy, or the enlargement of the muscle fibers due to added protein. Scientists 
have been able to create larger muscles across many species only by increasing the overall size 
of muscle fibers. Though much research has been conducted regarding broiler myogenesis, no 
studies have examined the effect of nicotinamide riboside and its effects on prenatal and 
postnatal muscle growth in broiler embryos.  
Cyclins D1, D2, and D3 are important regulators of the cell cycle both prenatally and 
postnatally. These D cyclins are factors that drive cells to go through the G1 phase of the cell 
cycle (Giannattasio et al., 2018). Cyclin D’s will subsequently activate Cyclin E, which  
transitions cells from G1 to the synthesis phase (Sherr, 1995). D-type cyclins can be activated by 
many environmental influencers such as stress, nutrients, and hormones (Fajas, 2013). Each D 
cyclin has shown to have different effects on skeletal muscle. Cyclin D1 has been shown to 
inhibit mitochondrial function (Fu et al., 2005). However, higher levels of Cyclin D1 
corresponds to an onset of myogenesis (Zhang et al., 1999). Lower levels of Cyclin D3 leads to a 
muscle fiber type shift in skeletal muscle towards more oxidative fibers (Giannattasio et al., 
2018). High levels of Cyclin D3 are found in differentiated myotubes (Ciemerych et al., 2002). 
There have been no studies examining the effect of nicotinamide riboside of Cyclin D levels in 
skeletal muscle.  
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 NICOTINAMIDE RIBOSIDE 
 Nicotinamide riboside compound 
Nicotinamide riboside (NR) is a nucleoside, which combines both the nicotinamide and 
riboside molecules into one. Nicotinamide riboside is a form of vitamin B3 and is only found in 
trace amounts in few foods, including products made with yeast as well as milk-derived foods. 
Although naturally occurring, the quantity of NR found in these foods are very low (Chi and 
Sauve, 2013). In recent years, new ways to synthesize NR have become available. One company, 
Chromadex, has created a process of manufacturing NR in yeast, making large quantities of the 
vitamin obtainable. Their brand of NR supplements specifically made for human use, called 
NIAGEN, is now readily available to the public (Chromadex Incorporated, Irvine, California, 
USA). 
Nicotinamide riboside is a nicotinamide adenine dinucleotide (NAD+) precursor and 
multiple studies demonstrated NR increased NAD+ levels in many species including yeast, 
rodents, and humans (Belenky et al., 2007; Khan et al., 2014; Martens et al., 2018). 
Nicotinamide adenine dinucleotide is essential for many metabolic processes in the body, but 
levels of NAD+ decline as age increases (Yoshino et al., 2011). With the augmented levels of 
NAD+ observed with supplementation of this compound, NR is hypothesized to improve 
metabolic function. Other forms of vitamin B3, including Nicotinic Acid (NA) and nicotinamide 
mononucleotide (NMN), are also NAD+ precursors but have shown to not be as effective as NR 
(Bitterman et al., 2002). Without proven adverse side effects of NR and with an increase in 
NAD+ levels and metabolic functions, nicotinamide riboside may be widely adopted for 
maintaining health in both humans and animals. 
 7 
 Administration and dosage of NR 
 The administration of NR has varied between each study. For cell culture studies, NR 
was supplemented directly into the culture itself at levels spanning 0.1mM to 1mM. (Canto et al., 
2012; Frederick et al., 2016; Agerholm et al., 2017; Fletcher et al., 2017). In live trials for mice 
and rats, the majority of studies mixed NR into the feed at amounts of 300-400mg/kg/day (Canto 
et al., 2012, Khan et al., 2014; Ryu et al., 2016; Zhang et al., 2016); however, Canto et al. (2012) 
administered NR through feed and water with 10mM NR. In a human study, NR was 
supplemented as pills with a tested level of 500mg (Martens et al., 2018).  
 Effect on NAD+ concentration 
Nicotinamide Adenine Dinucleotide is a compound essential for the body and partakes in 
helping to transfer energy from nutrients. Nicotinamide Adenine Dinucleotide also plays a large 
role in aging by activating proteins called sirtuins, which are important for mitochondrial 
function. Many studies demonstrate NAD+ levels have an inverse relationship with age, with the 
highest quantity found in newborns (Yoshino et al., 2011; Massudi et al., 2012). Therefore, it is 
important to provide alternative ways to stimulate NAD+ quantity improvements.  Nicotinamide 
riboside is able to be converted to NAD+ in two different ways, as covered by Chi and Sauve 
(2013) and Frederick et al. (2016). Before the conversion takes place, NR must be transferred 
into the cells.  One path starts with NR converting to nicotinamide (NAM), which is then 
converted to NMN. In the second pathway, NR is immediately converted to NMN. In both 
pathways, NMN is phosphorylated to NAD+. By increasing levels of NR available to cells, more 
NAD+ can be created for utilization.  
 As mentioned previously, supplementation of NR increased levels of NAD+ in the 
majority of studies. This result has been seen across several species. Originally, research focused 
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on yeast. In wild-type yeast strains, cells were given 10mM NR in culture and saw a positive 
increase of about 150% in the amount of NAD+ over time (Belenky et al., 2007). Many studies 
show similar effects of increased NAD+ levels in murine cell lines. Cell lines from mice were 
utilized for NR supplementation at different levels and exhibited enhanced levels of NAD+ 
(Canto et al., 2012; Frederick et al., 2016; Agerholm et al., 2017; Fletcher et al., 2017).  Both 
Canto et al. (2012) and Flethcher et al. (2017) found 0.5mM of NR in culture with mice cell lines 
had improved levels of NAD+ over that of controls, while Canto et al. (2012) and Frederick et al. 
(2016) also saw similar increases in NAD+ with a larger concentration of 1mM NR in culture. 
Though lower amounts of NR were used including 0.05mM, 0.1mM, and 0.2mM in the Canto et 
al. (2012) study, maximum NAD+ enhancement occurred at the higher levels of 0.5mM and 
1mM of NR. A study done by Yang et al. (2007), added different levels of NR from 0mM to 
0.6mM to human embryonic kidney cells in culture and found up to a 157% in NAD content 
increase compared to controls when using 0.6mM of NR. Agerholm et al. (2017) utilized cell 
lines from nicotinamide phosphoribosyltransferase (NAMPT) knockout mice, a mutation 
characteristic of a decline in NAD+. With supplementation of NR, NAD+ concentration was 
restored to normal levels equivalent to that of the controls.  
  Aside from cell culture, NR’s effect on NAD+ concentration is also consistent when 
provided as an oral supplement in mice. Studies from Canto et al. (2012), Khan et al. (2014), and 
Ryu et al. (2016) all utilized a dosage of 400mg/kg/day of NR as a feed additive and found 
amplified quantities of NAD+ in skeletal muscle compared to the controls, though 
supplementation took place at different ages and had diverse lengths of supplementation. In one 
study multiple tissues were tested for NAD+ content after oral supplementation, and NR was 
found to have increased NAD+ levels in the skeletal muscle and liver tissues of these mice by 
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60% and 40% respectively. There were no differences found in NAD+ content in the tissues 
from the brain or white adipose tissue. (Canto et al., 2012).  
Age at NR feeding does not affect the ability of NR to improve NAD quantity. Zhang et 
al. (2016) fed NR to mice aged 1 month as well as to mice aged 22-24 months for six weeks. At 
both ages, NR boosted the amount of NAD+ found within muscle stem cells. For the young 
mice, NAD+ was increased by 70% while in old mice NAD+ was boosted by about 140% 
(Zhang et al., 2016). Cellular mutation in mice also does not hinder the consistency of results 
when adding NR to the diet. Similar to the Agerholm et al. (2017) study with the NAMPT 
knockout mice cell lines, Frederick et al. (2016) tested mice with the same mutation and found 
consistent results and increased NAD+ concentration within the skeletal muscle.  
Only one study to date have examined the effect of NR on human subjects and levels of 
NAD+. In humans with an average age of 65, taking 500 mg of NR twice a day for six weeks 
resulted in a 60% increase in NAD+ compared to those who received the placebo (Martens et al., 
2018). The results shown through many studies across species are in agreement and show 
conclusive evidence that Nicotinamide riboside can be an effective additive to increase levels of 
NAD+ in the body.  
 Effect on mitochondria 
 Nicotinamide riboside has also affected metabolic processes by modifying mitochondria 
content. Mitochondria are commonly known as the powerhouses of cells due to their 
participation in energy production. Mitochondria take oxygen and nutrients and convert this into 
Adenosine Triphosphate (ATP) during the Tricarboxylic Acid (TCA) cycle. Mitochondria are 
indirectly affected by NAD+ quantity due to the fact that NAD+ activates sirtuin activity. 
Greater amounts on NAD+ will amplify sirtuin activity. Sirtuins are proteins imperative for 
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cellular processes including cell stress resistance, cellular aging and apoptosis, and mitochondria 
biogenesis (Mendelsohn and Larrick et al., 2017). If NAD+ concentration is too low, sirtuin 
activity decreases and mitochondrial function deteriorates.  
 Quantity as well as quality of mitochondria are important for metabolic function. 
Amplifying the number of overall mitochondria improves cellular function and oxidative 
phosphorylation due to enhancement of the rate at which mitochondria can produce energy. The 
condition of mitochondria is also an essential characteristic for metabolic processes. Having the 
correct mitochondrial structure and high amounts of cristae also enhances cellular function. 
Cristae are membranes that increase the surface area inside of the mitochondria, allowing more 
space for oxidative phosphorylation to occur and improving energy production (Rampelt et al., 
2017).   
 Changes in mitochondria numbers can be attributed to NR due to the modifications made 
in NAD+ levels. These mitochondrial alterations have been represented in many scientific 
studies (Canto et al., 2012; Khan et al., 2014; Ryu et al., 2016; Zhang et al., 2016). In healthy 
mice, Canto et al. (2012) found that the NR-fed treatment group, compared to the controls, had 
an increased mitochondrial protein and mitochondrial DNA in the skeletal muscles. 
Nicotinamide riboside supplementation had similar improvements in mice with mitochondrial 
and muscular diseases. In deletor mice, or mice with mitochondrial myopathies, daily addition of 
NR to feedings raised the volume of mitochondria (Khan et al., 2014). Ryu et al. (2016) 
examined myoblasts from mice with muscular dystrophy. After only 12 hours of administration 
of NR, the mutated myoblasts had increased mitochondrial protein, mitochondrial DNA, and 
oxygen consumption rate, which is indicative of amplified mitochondrial function and increased 
mitochondria amount. In aged mice, Zhang et al. (2016) also reported increased mitochondrial 
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function by means of enlargement of mitochondrial membrane potential, which corresponded to 
a greater energy capacity in the mitochondria and a greater synthesis of ATP (Zorova et al., 
2017).  As shown by many studies, supplementation of NR in both culture settings for in vitro 
studies as well as in diets for in vivo studies has shown positive effects on mitochondrial 
magnitudes.   
 Along with NR affecting mitochondrial quantities, the quality of the existing 
mitochondrial is positively affect as well (Canto et al., 2012; Khan et al., 2014).  A 
mitochondrial myopathy in deletor mice instigated abnormal, swollen mitochondria, but with the 
addition of NR, the number of cristae increased and the irregular structural impairments were 
restored to normal shape and size (Khan et al., 2014). Similarly, Canto et al. (2012) also depicted 
and increase in mitochondrial cristae with NR by about 400%. These improvements in 
mitochondrial structure enhance mitochondrial ability. 
 Effect on Adenosine Triphosphate 
 Due to the fact that nicotinamide riboside has proven advantageous for mitochondrial 
function and that mitochondria are important for the production of energy, we would expect to 
see an effect on ATP. This has been confirmed in several scientific trials (Khan et al., 2014; Ryu 
et al., 2016; Frederick et al., 2016; Zhang et al., 2016). In both young and aged mice, NR 
increased ATP content in muscle cells. Though younger mice have overall higher ATP levels in 
general, the addition of NR to aged mice resulted in ATP levels that mimic healthy young mice 
(Zhang et al., 2016). In both mitochondrial myopathy mice as well as NAMPT knock-out mice, 
ATP levels are smaller than that of control mice. With the supplementation of NR, two studies 
showed ATP concentration was transformed to match the ATP concentration of the control mice 
without mutations (Khan et al., 2014; Frederick et al., 2016). Similarly, muscular dystrophy mice 
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have significantly lower levels of ATP than customary, but analysis post-supplementation with 
NR, show normal and affected mice have identical levels (Ryu et al., 2016).  
 Effect on overall body weight 
 Nicotinamide riboside has proven to have many positive effects at the cellular level. On a 
larger scale, only one study has examined the effect on overall body weight as well as body 
weight gain (Canto et al., 2012). NR did not affect overall body weight of mice in experiments 
on a regular chow diet with or without the addition of NR. However, when mice were given a 
high fat diet in an obesity experiment, Canto et al. (2012) discovered that NR mice did have a 
decreased body weight compared to controls. This reduction in body weight was due to a 
significantly lower fat mass compared to mice who were not fed NR on a high fat diet.  
 
 Effect on skeletal muscle 
 With increased levels of NAD+, mitochondria, and ATP found in muscle, some studies 
have also examined the effects on the overall skeletal muscle growth though results have not 
been consistent. (Canto et al., 2014; Frederick et al., 2016; Ryu et al, 2016). With the addition of 
NR, healthy mice displayed similar muscle mass as compared to the controls who were not fed 
the supplement (Canto et al., 2014). Different results were observed in mice with muscular 
dystrophy with low muscle tone. Once fed NR for 12 weeks, there were no differences in overall 
lean mass in muscular dystrophy mice and the controls (Rye et al. 2016). In NAMPT knock-out 
mice, Frederick et al. (2016) exhibited that at 3 months of age, these mice showed no differences 
in muscle mass in the gastrocnemius and quadriceps muscles, but by 7 months of age these 
mutated mice had significantly less muscle mass. By supplementing NR in the feed for 6 weeks, 
these two muscles in the NAMPT knock-out mice were no longer smaller than controls. 
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Different circumstances may trigger different reactions in overall skeletal muscle growth from 
NR supplementation. 
  Nicotinamide riboside has the potential to influence skeletal muscle growth in some 
instances, and these same studies examine the effects on muscle fiber transformations (Canto et 
al., 2012; Frederick et al., 2016; Ryu et al, 2016; Zhang et al., 2016).  Muscle fiber oxidative 
property, fiber size, and fiber number are all indicative of skeletal growth and function. Canto et 
al. (2012) completed a Succinate dehydrogenase (SDH) stain on skeletal muscle fibers from the 
gastrocnemius muscle. The SDH staining procedure stains for fiber types based off of oxidative 
capacity. Other studies have focused on fiber size alterations after NR, though none have looked 
at muscle fibers from healthy mice. Two studies by Frederick et al. (2016) and Ryu et al. (2016) 
analyzed fiber sizes in unusual mice models. In NAMPT knock-out mice, skeletal muscle fiber 
size is significantly smaller than that of healthy mice. With the addition of NR to feed, fiber size 
of these affected mice is enlarged, though not to the size of normal mice (Frederick et al., 2016). 
In mice with muscular dystrophy, NR supplementation initiates both an increase in fiber cross 
sectional area (CSA) and the minimal muscle fiber diameter, compared to mice who were not 
given NR (Ryu et al., 2016). Only one study utilized NR to look at repair of fibers after muscle 
damage. Zhang et al. (2016) reported significantly more regenerating muscle fibers from mice 
fed NR than mice who were not. They attribute improvement in regeneration to the fact that 
supplementation with NR nearly doubled the amount of muscle stem cells in aged mice (Zhang 
et al., 2016).  
 Effect on skeletal muscle performance and aging 
 With all of the positive effects nicotinamide riboside has on the biological processes and 
growth of skeletal muscle, few studies have examined how this can affect performance and 
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endurance of the muscles (Canto et al., 2012; Frederick et al., 2016; Kourtzidis et al., 2016; Ryu 
et al., 2016; Zhang et al., 2016). Canto et al. (2012) tested healthy mice muscle performance 
using a treadmill test and found that NR supplementation significantly increased distance run by 
over 200 meters compared to mice who were not given the vitamin. Nicotinamide riboside 
lengthened the amount of time and distance ran in aged mice as well as improved grip strength in 
aged mice (Zhang et al., 2016). Ryu et al. (2016) also looked at skeletal muscle function in 
muscular dystrophy mice and saw that when fed NR for 7 weeks, mice had an improved grip 
strength by about 33% compared to muscular dystrophy mice who were not given NR. In the 
NAMPT knock-out mice model studied by Frederick et al. (2016), NR was able to restore peak 
twitch force of muscle to the same level as mice without the defect. Due to beneficial effects of 
NR on other skeletal muscle aspects such as NAD+ levels, mitochondrial biogenesis, and ATP 
production, most journals speculate that nicotinamide riboside would have positive influences on 
muscle performance. Contradictory to this, only one opposing study by Kourtzidis et al. (2016) 
demonstrated a negative result from NR. Treatment consisted of 300mg/kg/day for 21 days and 
was given to male rats. After this supplementation period, a tendency for these rats to have a 
worse performance in a swimming endurance test (Kourtzidis et al., 2016). Though NR affected 
rats in this study negatively, in other experiments, NR had a beneficial outcome. 
 Other studies focused on if aging of skeletal can be delayed with the use of NR 
(Frederick et al., 2016 Zhang et al., 2016). Zhang et al. (2016) determined reversal of muscle 
damage due to aging is possible with administration of NR. After muscle damage, significantly 
more fibers regenerated. This study speculates that repairing of muscle was due to a significant 
increase in muscle stems cells after supplementation. Zhang et al. (2016) also examined aged 
mice, 22-24 months, as compared to young mice at 1 month of age. As mentioned previously, 
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certain biological levels and functions decrease with aging. But, when using NR as a feed 
additive, the levels of ATP, number of stem cells, and muscle performance were all brought back 
to levels of 1month old mice. Aged mice even had higher levels of NAD+ than that of young 
mice and, accordingly, it is believed that aging could be slowed, or reversed, with NR. In 
concurrence, Frederick et al (2016) saw that muscle deterioration was reversible with the 
application of NR, leading to the belief that this b3 vitamin can help slow the aging process of 
skeletal muscle. 
 Effect on cardiac muscle 
 Though many studies utilizing NR have also looked at the effects of skeletal muscle, only 
one study to date has also examined the impact of NR on cardiac muscle. In mice with muscular 
dystrophy, Ryu et al. (2016) observed both skeletal and cardiac muscle post NR administration. 
In the case of muscular dystrophy, often deaths eventually occur due to heart failure (Moat et al., 
2013). Feeding 400mg/kg/day of NR for a duration of 12 weeks, resulted in a reduction of 
cardiac fibrosis, or the thickening and scarring of the connective tissue in the heart. Addition of 
NR to the diet also decreased the amount of necrosis of cardiac muscle cells and reduced 
inflammatory cell infiltration in the heart of muscular dystrophy mice (Ryu et al., 2016). This 
study demonstrates a possibility of NR to improve both skeletal and cardiac muscle.  
 IN OVO INJECTION IN BROILERS 
 Injection location and day of administration 
 Currently in the poultry industry, most commercial broiler hatcheries employ in ovo 
technology to vaccinate embryos at day 17 to 19 of incubation to prevent Marek’s disease, 
Newcastle disease, and Infectious Bursal disease (Merck Veterinary Manual, 2018). Many 
studies in the literature were completed to determine the most effective site of vaccination. 
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Throughout the incubation period, there are several possible locations for in ovo injections to 
occur including the air cell, allantoic membrane, amniotic fluid, the yolk, the albumen, and in 
very late stages of development, the embryo body (Roto et al., 2016). Avakian et al. (2002) 
focused specifically on a Marek’s disease vaccination and injected into four locations, the air 
cell, allantoic sac, amniotic fluid, and the embryo at d18 of incubation. The protective index, a 
percentage of effective immunity, for these injection sites were scored as 0, 26.3, 94.4, and 93.9, 
respectively, demonstrating that in ovo injection for vaccinations was most effective in the 
amniotic fluid and into the embryo itself. While these vaccinations occurred in late term 
embryogenesis, many studies observed the subsequent results of injections at multiple locations 
and different developmental time points.  
 Though various studies have applied in ovo technology, only few have monitored its 
effects on overall body and skeletal muscle growth. These same studies have developed different 
strategies for in ovo treatment and for injection positioning. According to Roto et al. (2016), the 
most common injection sites are into the air cell and the yolk sac of a broiler egg. Only two 
studies examining the overall body growth or skeletal muscle growth applied the air cell 
injection technique (Bhanja et al., 2015; Bednarczyk et al., 2016). The purpose of an air cell in 
an egg is to provide oxygen for the chick when it is ready to hatch. The contents placed into the 
air cell will not be directly incorporated into the embryo like other injection sites. Similarly, in 
two other studies, injection of treatment took place into the yolk of the egg (Kim et al., 2007; 
Macalintal et al., 2012). The yolk in a fertilized egg becomes the nutrition that the embryo will 
ingest and by the end of embryogenesis will be absorbed into the chick. Post-hatch, the contents 
of the remaining yolk will be absorbed into the intestines. (Speier et al., 2012). Both 
McReynolds et al. (2000) and Araujo et al. (2018) placed in ovo injections into the amnion of the 
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developing embryo, which is the sac directly surrounding the broiler embryo and is thought to be 
a form of protection for the maturing embryo. Several studies have observed injections into the 
albumen of the egg (Kocamis et al., 1998; Kim et al., 2007; Liu et al., 2012). The albumen of the 
egg provides water and some nutrients to the developing embryo (Willems et al., 2014). 
Abousaad et al. (2017) applied in ovo technology in a manner similar to current vaccinations of 
broiler embryos, directly to the body. This ensures that the embryo itself will directly receive 
treatment. Not only does the location of injection affect how treatment is received by the 
embryo, time of injection during the gestational period also plays a very large role to how 
treatment may affect the body and its functions.  
 Researchers have varied times at which injection takes place to potentially affect growth 
of certain tissues. The day at which this takes place will affect certain developments, depending 
on what structures are being formed at that time point. By day three of embryogenesis, both the 
brain and heart can be discerned. On days 3-7, organs continue to develop, primary myogenesis 
occurs, and limb buds are evident. Around day 8, the brain is fully in place and secondary 
myogenesis begins. After this point, growth of the bird-like features and overall size increases 
occur. In the last few days before hatching, the yolk is absorbed into the embryo and the chick 
prepares for hatch (Warin et al., 2009; Chal and Pourquie, 2017). 
 Liu et al. (2012) and Bhanja et al. (2015) administer injections on day zero, before 
incubation took place. Other studies also performed injections in the early stages of development 
between the days of three and seven, with the potential to affect both organ and skeletal muscle 
growth (Kocamis et al., 1998; Kim et al., 2007). Some researchers have chosen to inject midway 
through the gestational period, on days 10-12. (Hargis et al., 1989; Macalintal et al., 2012; 
Bednarczyk et al., 2016). These treatments would not be able to affect the formation of the 
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organs or of primary myogenesis, but could theoretically affect secondary myofibers and the 
subsequent growth. The injections implemented by McReynolds et al. (2000) and Araujo et al. 
(2018) were given at days 18 and 17.5, respectively. Though growth of the embryo is almost 
complete at this point of gestation, treatments given at this time have the chance to be absorbed 
into the body and consequently impact post-hatch development.  
 Effect on hatchability 
 In the United States, the egg fertility rate in the commercial broiler industry is about 94% 
with a hatchability rate of 85% (Cobb-Vantress, 2018). In ovo injections sometimes cause 
hatchability of broiler chicks to decrease (Kocamis et al., 1998; Kim et al., 2007; Macalintal et 
al., 2012). This is due to either the injection technique, the compound that is injected into the 
egg, or a combination of both technique and compound. Treatments can be given to the embryo, 
but only at an acceptable concentration to prevent death of the embryo. When injecting insulin-
like growth factor 1 (IGF-1) into the albumen of the egg in the early days of embryogenesis, the 
hatchability was only 76.4% compared to the control that was not injected with a hatchability of 
92.7% (Kocamis et al., 1998).  Similarly, Kim et al. (2007) injected an anti-myostatin antibody at 
day 3 of embryogenesis into the yolk, which resulted in a 15.5% decreased in hatchability 
compared to the eggs that did not receive an injection. Though in this study, overall hatchability 
was low, with the controls only hatching about 68% of its broiler chicks. In the Macalintal et al. 
(2012) study, injection of Selenium at day 10 of incubation into the yolk of the fertilized egg led 
to only a 66% hatchability rate of broiler chicks. Not all in ovo injections cause decreases in the 
rate of hatch (Araujo et al., 2018). Five levels of vitamin E (VE) injections at day 17.5 of 
incubation resulted in varying hatch rates, though all were greater than the expected 85% 
hatchability. The largest VE injection of 60IU resulted in the highest hatchability rate of 92% 
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and the injection containing no VE had the smallest hatch rate of 86% (Araujo et al., 2018). 
Based off the findings of these studies, negative effects on hatchability rate often come from in 
ovo techniques requiring injections during the first half of embryogenesis, while injections 
occurring close to the day of hatch have no effect on hatchability.  
 Effect of in ovo treatment on overall weight 
 Several studies have used in ovo treatments to impact the overall growth and weight of 
the bird. Those that have, have incorporated different compounds into the injection solutions. 
None of these practices have integrated the use of nicotinamide riboside and in ovo injection 
techniques. Injection solutions including Leptin, Selenium, Probiotics, and Casein during 
embryogenesis did not result in an increase in body weight compared to the controls throughout 
the entire experiments (Liu et al., 2012; Macalintal et el., 2012; Bednarczyk et al., 2016; 
Abousaad et al., 2017). Two in ovo studies initially did not demonstrate increases in body 
weight, but over time examined changes between treated broilers and controls (Kocamis et al., 
1998; Kim et al., 2007;). Kocamis et al. (1998) injected IGF-1 into fertilized broiler eggs during 
the first several days of incubation and saw no changes in body weight during weeks 0-5; but in 
the 6th week, birds treated with IGF-1 had significantly greater weights than the untreated birds. 
The anti-myostatin antibody injections at day 3 of development resulted in similar findings. 
From days 1-14, no differences in body weight were observes; however, male broilers treated 
with the antibody had increased weights (Kim et al., 2007). Some compounds used in ovo 
technology have triggered significant differences in body weight (Hargis et al., 1989; Araujo et 
al., 2018). Hargis et al. (1998) injected a growth hormone into developing embryos and exhibited 
and increase in overall body weight of broiler chicks. Likewise, the injection of VE at day 17.5 
of incubation indicated that the largest levels did lead to an increase in body weight of chicks at 
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hatch compared to chicks not given VE. Though while this difference was statistically 
significant, the largest VE treatment weights were only about one gram larger than the control 
(Araujo et al., 2018). In ovo injections have led to variable results in body weight of broilers due 
to the diverse treatments tested in these studies.  
 Effect on organ characteristics 
 Several studies that injected solutions within the first three days of development did 
consider the impact on organ development (Kocamis et al., 1998; Kim et al., 2007; Bhanja et al., 
2015). An IGF-1 injection placed into the albumen produced an increase in heart weights from 
males, though no difference was observed for females from 42 day old broilers. This could be 
expected due to male birds being overall larger than females. Liver weights remained similar for 
IGF-1 treated birds versus controls (Kocamis et al., 1998). Kim et al. (2007) found concurrent 
results with an injection of an anti-myostatin antibody, and the hearts from male broilers were 
larger than females. The liver and spleen weights between treatments were similar (Kim et al., 
2007). Twenty-eight days post-hatch, Bhanja et al. (2015) also presented data indicating similar 
weights for the heart, liver, and spleen after injection of nano-silver particles before incubation of 
fertilized broiler eggs. None were able to find biologically significant alterations to organs from 
in ovo injections of these compounds. Studies in which injection took place during mid to the 
end of embryogenesis did not examine organ growth and development, likely due to the fact that 
organs are developed early on in the gestation period.  
 Effect on skeletal muscle growth 
 The results are varied for studies evaluating the effect of in ovo technology on skeletal 
muscle growth. Both the injections of anti-myostatin antibody and silver nano-particles at days 
three and zero respectively, did not change the weight of the breast muscles in resulting birds 
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(Kim et al., 2007; Bhanja et al., 2015).  Though Kim et al. (2007) did not observe changes to the 
breast weight of broilers 28 days post-hatch, the thigh and leg weight of the birds given silver 
nano-particles into the yolk were smaller than that of the controls and the bird given the injection 
into the albumen. Some researchers have reported positive effects on skeletal growth with the in 
ovo injections of growth hormones, IGF-1, and leptin (Hargis et al., 1998; Kocamis et al., 1998; 
Liu et al., 2012). Kocamis et al. (1998) observed increases in both the leg and breast weight of 42 
day old broilers that were treated with IGF-1 in the albumen on day three of development. 
Likewise, levels of leptin in the albumen given to fertilized eggs before incubation led to an 
increase in the gastrocnemius muscle of both male and female broilers (Liu et al., 2012).  
 Other aspects of skeletal muscle quality from the breast muscle have been studied after 
the use of in ovo technologies (Kocamis et al., 1998; Macalintal et al., 2012; Araujo et al., 2018). 
Between the untreated broilers and the IGF-1 injected broilers, the percentage of moisture, fat, 
protein, and ash from the breast muscle was similar (Kocamis et al., 1998). Contrary to IGF-1 
injections, all levels of VE injected into the amniotic cavity resulted in an increase of protein 
found in the breast muscle of newly hatched chicks (Araujo et al., 2018). Macalintal et al. (2012) 
observed decreased oxidation in the breast muscle from broilers treated with selenium in the yolk 
midway through the gestational period. The outcomes of the muscle growth and quality 
examined in these studies are quite variable due to the differences in techniques and compounds 





Chapter 3 - The effect of in ovo injection of Nicotinamide Riboside 
on avian myogensis 
 ABSTRACT  
The objective of this study was to determine the effects of in ovo injection of 
nicotinamide riboside (NR) on avian embryonic myogenesis.  Before incubation, 
fertilized broiler eggs (n=156; Cobb 500) were randomly assigned to 1 of 4 treatments in a  
completely randomized design with a 2 × 2 factorial arrangement. Factor 1 was treatment 
(TRT), with eggs injected with 100 µl of 0.0 (-) or 2.5 mM (+) NR in sterile saline. Factor 2 
consisted of injection location (LOC), with treatments injected into the yolk (YO) or albumin 
(AL). Injection took place at d 10 of incubation. Twenty-four hours post-hatch, chicks were 
euthanized. Measurements including chick weight, head and chest measures, and left Pectoralis 
major (PM) weight and dimensions were collected. The left PM was used for muscle fiber 
analysis. There were no TRT×LOC interactions for all body and pectoralis major measures (P ≥ 
0.07), except PM weight and length (P < 0.01). Pectoralis major muscles from the YO+ 
treatment were heavier (P < 0.01) than all other treatments. Length of PM from AL+ were longer 
than control chicks injected into either the yolk or albumen (P < 0.04), but was shorter (P < 0.01) 
than YO+ chicks. All body measures were not affected by the main effects of TRT or LOC (P ≥ 
0.12), with the exception of chest width, in which YO chicks has wider chests (P = 0.01) than 
AL chicks. There was a TRT×LOC interaction for muscle fibers per 1000m2 with YO+ muscles 
having the largest number of fibers (P < 0.01) compared to all other treatments, which did not 
differ (P ≥ 0.16) from each other.  There were no TRT×LOC (P ≥ 0.43) interactions nor TRT or 
LOC main effects (P = 0.06) for muscle fiber cross sectional area. Treatment affected PM width 
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and depth (P > 0.01), with NR chicks having wider and thicker muscles 
that control chicks. Injecting NR into the egg of the developing broiler embryo increases PM 
muscle development and data would indicate greater positive effects when NR is injected into 
the yolk.   
Key Words: broiler, fiber cross-sectional area, in ovo injection, nicotinamide riboside, 
pectoralis major 
 













Obtaining food security for the world has been a pressing issue as the population 
continues to drastically increase. In the United States, poultry consumption over the past 60 years 
has also dramatically intensified by 229% (Nation Chicken Council, 2019). To meet the demands 
of escalating preferences for chicken, producers must either increase broiler production, increase 
their rate of growth, or increase the amount of muscle harvested from each bird. Myogenesis, or 
the formation of muscle, may be altered to potentially achieve an increase in rate of growth or 
skeletal muscle accumulation. Though overall body weight has increased and breast to feed 
conversion rate has decreased significantly in the past 60 years (Zuidhof et al., 2014), 
improvements could still be made to provide for the growing population. 
Nicotinamide riboside (NR) is a vitamin B3 analogue and has induced positive effects on 
skeletal muscle physiology. One known outcome of NR supplementation is protection of skeletal 
muscle against aging (Guarente et al., 2016; Fletcher et al., 2017), which has been thought to be 
due to increases in muscle satellite cells with the addition of NR (Zhang et al., 2016). Other 
studies have proved that with the oral supplementation of NR, biogenesis of mitochondria is also 
amplified after the addition of NR to the diet (Canto et al., 2012; Ryu et al., 2016). As a result, 
NAD+ levels within muscle were augmented as seen in both murine models by increases of 34-
142% (Khan et al., 2014; Zhang et al., 2016) and in the human model by about 60% (Martens et 
al., 2018). Biogenesis of mitochondria is also amplified after the addition of NR to the diet 
(Canto et al., 2012; Ryu et al., 2016). An increase in Adenosine Triphosphate (ATP) is also 
observed from NR treatment due to improvements to mitochondrial function (Khan et al., 2014; 
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Ryu et al., 2016; Frederick et al., 2016). Some studies also observed increased muscle mass and 
muscle performance (Frederick et al., 2016; Ryu et al., 2016).  
One approach to deliver NR to developing broiler embryos is in ovo injections. This 
technology is currently utilized for vaccine administration in the commercial poultry industry. 
Researchers have used in ovo injection of other supplements such as amino acids, carbohydrates, 
hormones, probiotics, and immunostimulants, leading to varied results on skeletal muscle and 
overall growth (Roto et al., 2016). Both injections of growth hormone as well as IGF-1 led to 
increases in skeletal muscle growth in the breast of broilers (Hargis et al., 1989; Kocamis et al., 
1998). While there are many studies examining the effects of NR supplementation on skeletal 
muscle in mice, none have been observed in broilers. Therefore, the objective of this study was 
to observe the effects of in ovo injection of nicotinamide riboside on overall growth 
measurements and skeletal muscle physiology.  
 MATERIALS AND METHODS  
 Egg Collection, Treatment Assignment, and Incubation 
 Fertilized broiler eggs (n = 156) with an average weight of 70.3 g (Cobb 500; Cobb 
Vantress, Siloam Springs, AR) were transported to Kansas State University (Manhattan, KS). 
Upon arrival, egg weights were recorded and eggs were ordered by weight. Within each 4 egg 
strata, eggs were randomly assigned to treatment within a 2  2 factorial arrangement. Factor 1 
was NR treatment with eggs receiving 0.0mM (-) or 2.5mM (+) NR. Factor 2 consisted of 
injection location, with treatments injected into either the yolk (YO) or albumen (AL). After 
treatment assignment, eggs were positioned with equal treatment representation onto trays and 
placed in an incubator (Sportsman 1502; GQF Manufacturing Company Inc., Savannah, GA) set 
to operate at a temperature of 37C and a relative humidity of 40  2% for the first 18 d of 
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incubation. The incubator rotated hourly to reposition eggs and the trays were rotated daily 
throughout the incubator to account for variation in temperature and humidity. Tray weights 
were recorded each day to determine egg weight loss percentage with a target weight loss of 
0.67% per day.   
 Solution Preparation and Injection Procedure 
 Solutions were prepared immediately prior to injection procedures. To achieve a 250mM 
solution, 6.38g of NR was added to 0.1L of 0.9% sterile saline and covered with foil to prevent 
exposure to light. To determine a final concentration in the egg, the average volume of the yolk 
from Cobb 500 eggs was determined to be 10mL. Injecting 100µl of the 250mM NR solution 
into the 10mL yolk led to a final concentration of 2.5mM NR. The albumin injection groups 
were given the same amount of 100µl of solution. The control group also received 100µl of the 
0.9% sterile saline. The injection solutions were stored at room temperature before and during 
the injection process. Sets of 20 eggs representing equal treatment numbers were removed from 
the incubator at a time. Eggs were candled to determine location of the yolk and albumen and the 
injection site was cleaned with 70% ethanol. Eggs were turned at a 90angle and a 2.54-cm, 20-
guage hypodermic needle was used to create an opening in the shell. The needle was pressed 
approximately 1 cm into injection site and 100l of the assigned treatment was expelled into the 
egg. A 1-cm2 portion of medical tape (Nexcare; 3M, Maplewood, MN) was positioned over the 
injection location and eggs were returned to the incubator.   
 Hatching, Euthanasia, and Processing 
 On d 18 of incubation, the relative humidity of the incubator was increased to 60  2% 
and eggs were placed into hatching boxes at the bottom of the incubator. As chicks began to 
hatch on d 21, they were removed from the incubator, marked for treatment, and relocated to a 
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box positioned underneath a heat lamp. Approximately 12 to 24 h after hatch, chicks were 
euthanized by prolonged exposure to CO2 gas and decapitation. Chick weights were recorded and 
calipers (Traceable Digital Calipers; Fisher Scientific, Pittsburg, PA) were utilized to measure 
crown to rump length (CR), head width, head length. Head and chest circumference were also 
collected by wrapping a string around the designated area and comparing the length of the 
measurement against a ruler. Chicks were sprayed with 70% ethanol, and the skin and feathers 
were pulled back to reveal the Pectoralis major muscles. Once exposed, the overall chest width 
and length were measured using digital calipers. Using a scalpel, the left and right PM muscles 
were removed, careful to not remove the Pectoralis minor muscles. The left PM was weighed 
and dimensions of this muscle were collected using digital calipers, including PM length, width, 
and depth. The left PM was positioned onto a tongue depressor and placed into a -80C freezer, 
where it was stored until used for histology sectioning. The right PM was stored in a 
microcentrifuge tube at -80C until further analyses. The heart and liver were also removed, 
weighed, and then discarded. 
 Histology and Immunohistochemistry 
The left PM was removed from the tongue depressor and embedded in tissue embedding 
media (Fisher Scientific), cooled with liquid nitrogen, and stored at -80C until further analysis. 
When sectioned, cuts were made parallel to the length of the PM muscle. Six cryosections were 
collected (10M thick) on positively charged slides (Diamond White Glass; Globe Scientific 
Inc., Paramus, NJ) and the methods of Noel et al. (2016) were followed for 
immunohistochemistry with modifications. Briefly, cryosections were incubated in a blocking 
solution containing 5% horse serum and 0.2% TritonX-100 in Phosphate Buffered Saline (PBS) 
for 30 min. Slides were incubated for 1 h at room temperature in a primary antibody solution 
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consisting of blocking solution and 1:500 -dystrophin (Thermo Scientific, Waltham, MA). 
Cryosections were washed 3 times for 5 min each in PBS and then incubated for an additional 30 
min with blocking solution containing 1:1,000 Alexa-Flour 594 goat-anti-rabbit heavy and light 
chains (Life Technologies; Carlsbad, CA). Cryosections were washed again as stated above, 5l 
of 9:1 glycerol in PBS was placed on each section, and coverslips were added for imaging. 
Cryosections were imaged at 200× magnification using a Nikon Elipse TI-U inverted microscope 
(Nikon Instruments Inc., Melville, NY). A Nikon DS-QiMC digital camera (Nikon Instruments 
Inc.) was used to photograph cryosections and an average of 1,000 fibers were analyzed using 
NIS-Elements Imaging software (Basic Research, 3.3; Nikon Instruments Inc.) to determine fiber 
cross-section area (CSA).  
 NAD+ Quantification 
 Skeletal muscle NAD+ content was quantified using the NAD+/NADH Assay Kit 
(Abnova, Taipei, Taiwan). Briefly, about 25mg of tissue from the right PM of two samples 
within the same treatment were pooled together to reach a weight of 50mg of muscle tissue. The 
pooled samples were homogenized in 100l of NAD extraction buffer. Samples were heated at 
60C for 5 min and 20 l assay buffer and 100 l of NADH extraction buffer were added. 
Samples were vortexed, centrifuged at 17,500 x g for 5 minutes, and the supernatants were 
extracted. Supernatants and the working reagent were aliquoted and absorbance was measured at 
565 nm at time points 0 and 15 minutes using a spectrophotometer (Eon; BioTek, Winooski, VT, 
USA).  The NAD+ concentration was calculated using the change in optical density (OD) by 
subtracting OD0 from OD15, deducting the OD value of the blank, and dividing that value by the 
slope of the NAD+ standard curve. (Data not presented). 
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 Statistics 
 Data were analyzed as a completely randomized design with a 2  2 factorial 
arrangement and egg as the experimental unit. All models were analyzed using the MIXED 
procedure of SAS 9.4 (SAS Inst. Inc., Cary, NC) with treatment (TRT) and injection location 
(LOC) as fixed effects. Statistical significance was set at P  0.05.  
 RESULTS 
 Body Morphometrics 
There were no TRT × LOC interactions for all measures (P > 0.07; Table 3.1), except PM 
weight and length (P < 0.01; Table 3.2). Pectoralis major weights of NR chicks injected in the 
yolk were greater than all other treatment groups (P < 0.01), which did not differ from each other 
(P > 0.09). Length of PM from NR chicks injected into the albumen was longer than control 
chicks injected into either the yolk or albumen (P < 0.04), but was shorter (P < 0.01) than NR 
chicks injected into the yolk. Treatment did not affect whole body or organ measures (P > 0.12; 
Table 3.1); however, NR treatment did increase length, width, and depth of PM (P < 0.01). The 
main effect of location showed no effects (P > 0.06), with the exception of an increased chest 
width and PM weight when injection took place in the yolk (P  0.01). 
 Muscle Fiber Characteristics 
 There was no TRT × LOC interaction for muscle fiber CSA (P = 0.73; Figure 3.1). 
Neither treatment nor location affected muscle fiber CSA (P ≥ 0.06). There was a TRT × LOC 
interaction for muscle fiber number per 1000 square microns (P < 0.01; Figure 3.2). There were 
no differences between treatments injected into the albumin or between NR injected into the yolk 
(P ≥ 0.16); however, when NR was injected into the yolk of the egg, muscle fiber number was 
significantly larger than all other treatments (P < 0.01). 
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 NAD+ Quantification 
 At the time of publication of this thesis, NAD+ data was proprietary. This data is 
expected to be published in a peer reviewed journal at a later date. 
 DISCUSSION 
 Body Morphometrics 
 Over the last 60 years, poultry consumption has increased by 229% (USDA, 2018). To 
keep up with demand, the industry has improved rate of growth in broilers with decreased market 
age and increased market weight (National Chicken Council, 2018). Poultry scientists are 
investigating ways to capitalize on poultry growth. In the past, in ovo injected growth hormone 
did increase poultry growth by increasing overall body weight (Hargis et al., 1989); however, in 
present day, consumers no longer are tolerable towards growth hormones.  Due to these 
consumer preferences, several studies have examined the effects on injecting alternatives that 
consumers may find more favorable. Although, these same studies report no effects on overall 
body weight of chicks after in ovo injections with differing compounds including selenium, 
probiotics, and vitamin E (Macalintal et al., 2012; Bednarczyk et al., 2016; Araujo et al., 2018). 
Research studies have yet to examine the effects of nicotinamide riboside on whole body and 
skeletal muscle growth in meat producing animals, including in ovo injection of NR in broilers. 
However, several studies have looked at the effect of NR on these qualities in rodents. Under 
normal diet conditions, mice fed NR did not show changes in body weight (Canto et al., 2012). 
Addition of NR only affected overall body weight in mice fed high-fat diets, with mice 
supplemented with NR gaining less weight than mice that were not given NR (Canto et al., 
2012).  In the current study, in ovo injection of NR into either location did not affect overall body 
weight in hatched chicks. This is supported by the fact that NR injection also did not affect any 
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other whole body measurement for d 21 hatched chicks. Overall, the lack of significance on 
overall body weight of the current study are similar to literature regarding in ovo injection 
studies of other vitamins and minerals as well as similar to the addition of NR in the feed of 
rodents under normal conditions. 
 As seen with overall body weight, only in ovo injection with growth hormone 
successfully increased the breast muscle weight (Hargis et al., 1989).  While NR has not 
previously been injected into broiler eggs, NR feed supplementation in rodents has resulted in 
varied effects across many studies. Canto et al. (2014) demonstrated that healthy mice fed NR 
had similar lean muscle mass compared to mice not supplemented with NR. Only under unusual 
circumstances did NR increase skeletal muscle mass in rodents. NAMPT knockout mice with 
characteristically lower muscle mass compared to normal mice, showed increases in skeletal 
muscle similar to control mice when fed NR (Frederick et al., 2016). Similar results in the 
muscular dystrophy model were observed in a study by Ryu et al. (2016).  Feeding NR to healthy 
mice did not lead to an increase in muscle mass; however, NR led to an increase in muscle mass 
of mice with muscular dystrophy by an average of 43% (Ryu et al., 2016). In the current study, 
only injection of NR into the yolk of the egg led to a 35% increase in PM weight. Additionally, 
injection of NR into both the yolk and the albumin increased PM length by an average of 14%. 
These differing results among studies may be due to the prenatal method at which NR was 
delivered to broiler eggs in the current study, whereas in past studies NR was given as a daily 
feed additive in mice postnatally. 
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 Muscle Fiber Characteristics 
 In previous literature regarding use of NR, muscle fiber CSA has been examined only in 
the NAMPT knockout and muscular dystrophy mice models which characteristic of smaller 
muscle fibers. In both cases, increases in muscle fiber CSA were reported with the addition of 
NR in the diet (Frederick et al., 2016; Ryu et al., 2016). In the current study, the results reported 
were contrasting to previous literature. Fiber CSA was not altered due to an injection of NR into 
either location and fiber size was similar across all treatments.  
These findings would indicate that the overall growth of the PM observed was not due to 
changes in size of the muscle fibers. For growth to have occurred without an increase in fiber 
size, fiber number was altered. In the current study, fiber number per 1000m was increased by 
37.9% when an injection with NR took place in the yolk of the developing egg. No other studies 
concerning either NR or in ovo injections evaluated muscle fiber number. Due to the fact that in 
past literature, NR was given postnatally, fiber number could not be altered in previous rodent 
studies, whereas in the current study, NR was injected prenatally. While fiber size was not 
altered by NR injection into either the yolk or albumin, fiber number was significantly increased 
in the YO+ treatment. Overall, the current study’s findings were not comparable to past 




 Injection of 2.5 mM nicotinamide riboside at d 10 in incubation into both the yolk and 
albumin did not affect overall body growth or organ weight in hatched broiler chicks; however, 
skeletal muscle from the pectoralis major was altered. Increased PM weight was observed from 
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chicks given NR into the yolk of the egg. Length of the PM was also increased by injection of 
NR into both locations, though the longest muscles came from chicks that were supplemented 
with NR in the yolk. While muscle fiber size in the PM was unchanged by treatment and 
injection location, muscle fiber number was increased by the YO+ treatment. These findings 
indicate that while body measurements were unchanged, positive transformations were made to 
PM muscle size and fiber number with a 2.5mM injection into the yolk. Overall, the new 
injection technology may be a solution to improving growth rate in broilers and could be utilized 
to meet the consumer demand for chicken.  
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Table 3.1 Whole body muscle measurements from hatched broiler chicks injected with 0mM Nicotinamide Riboside (NR) in 
0.9%sterile saline or 2.5mM NR in 0.9% sterile saline into either the yolk (Y) or albumin (A) at day 10 incubation 
 Treatment  
 0  mM NR 2.5  mM NR  P-values 
Item  A Y  A  Y SEM TRT1      LOC2 TRTLOC 
Chick weight, g  42.69.... 42.99 43.19 44.02 6.4 0.17 0.31 0.63 
Body measurements, mm         
Crown-rump length 95.60 96.93 96.14 89.36 3.70 0.12 0.23 0.07 
Head width 15.40 15.74 15.56 15.45 0.40 0.67 0.48 0.21 
Head length 21.79 21.86 21.29 21.73 0.19 0.42 0.51 0.63 
Head circumference  32.38 32.08 32.14 31.49 1.60 0.70 0.66 0.87 
Chest length 22.01 21.96 21.98 22.68 0.55 0.36 0.39 0.29 
Chest width 16.90 17.35 16.57 17.69 0.33 0.98 0.01 0.28 
Heart weight, g 0.36 0.36 0.35 0.36 0.02 0.75 0.55 0.24 
Liver weight, g 1.09 1.08 1.05 1.11 0.06 0.64 0.36 0.19 
abc of treatment within row differs (P < 0.05). 
1TRT = treatment of 0 mM or 2.5mM NR in 0.9% sterile saline.  
2 LOC = location of injection. 
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 Treatment  
 0  mM NR 2.5  mM NR  P-values 
Item A Y A Y SEM TRT1 LOC2 TRTLOC 
Pectoralis major weight, g 0.13a 0.13a 0.14a 0.18b 0.01 <0.01. <0.01 <0.01. 
Pectoralis major 
dimensions, mm 
        
Length 17.55a 17.04a 18.68b 20.74c 0.43 <0.01. 0.06 <0.01. 
Width 4.59 4.62 4.81 5.21 0.22 <0.01. 0.13 0.20 
Depth 2.27 2.32 2.43 2.65 0.09 <0.01. 0.09 0.30 
abc of treatment within row differs (P < 0.05). 
1TRT = treatment of 0 mM or 2.5mM NR in 0.9% sterile saline.  




Table 3.2 Pectoralis major measurements from hatched broiler chicks injected with 0mM Nicotinamide Riboside (NR) in 0.9% sterile 




Figure 3.1 Muscle fiber cross-sectional area (CSA) from the pectoralis major (PM) of hatched broiler 
chicks injected with 0 mM nicotinamide riboside (NR) in 0.9% sterile saline or 2.5mM NR in 0.9% 
sterile saline into either the yolk (Y) or albumin (A) at day 10 of incubation. The PM muscle was 
embedded in a sectioning compound, sectioned onto a slide, and stained with Dystrophin antibody 
(Thermo Scientific). For each sample, the area of 1000 fibers were analyzed on the NIS-Elements 










Chapter 4 - Increasing the concentration of in ovo injected 
Nicotinamide Riboside has a positive influence on avian myogenesis 
 ABSTRACT  
The objective of this study was to determine the effect of nicotinamide riboside concentration on 
avian embryonic myogenesis. Fertilized broiler eggs (n=420; Cobb 500) were randomly assigned 
to 1 of 4 treatments:  0.0, 2.5, 5.0, or 10.0 mM NR made in 0.9% sterile saline. Eggs were 
assigned to day of euthanasia on d15 of embryonic incubation, d19 of embryonic incubation, or 
d21 after hatch. At d10 of incubation, 100l of allotted treatment was injected into the egg yolk. 
Eggs were incubated at 37±3°C and 40±2% relative humidity for 18 days and raised to 60±2% 
for the final 3 days. At all time points, embryos and chicks were euthanized. Measurements 
collected include: body weight; crown-rump length; chest and head measures; organ weights; 
and either chest plate weight and dimensions at d15, or left Pectoralis major (PM) weight and 
dimensions at d19 and d21.  Leg area and muscle fiber characteristics were analyzed. There was 
no treatment effect on body measures for d15 embryo weight (P≥0.23). For d19 embryos and 
d21 chicks, there were no treatment differences for body measures (P≥0.08), excluding head 
circumference in d19 embryos and head length and chest width in d21 chicks. Head 
circumference was increased (P=0.04) in the 5 and 10mM d19 embryos, while d21 chick head 
length and chest width were larger (P≥0.05) from 2.5mM NR. There was no treatment effect 
(P≥0.22) for d15 chest plate measures; however, d19 PM weight and length were increased 
(P<0.01) at all NR levels. The weight and width of chick PM were increased (P<0.01) at every 
NR level. Chicks given 2.5 and 5mM NR had longer PM measurements (P≤0.01) than saline 
chicks. Injection of 5mM NR increased PM depth (P≤0.04) from d21 chicks. Treatment did not 
 39 
affect leg muscle area or muscle fiber CSA (P≥0.20). All NR injections increased muscle fiber 
number (P<0.01); though 10mM injection led to the largest increase in fibers (P<0.01). Injecting 
up to 5.0 mM NR in the yolk of the developing embryo did not affect body weight but increased 
PM measures, indicating NR influenced avian myogenesis.  








 Demand for poultry meat has continued to rise as chicken consumption has more 
than doubled over the past 60 years (National Chicken Council, 2019). A major goal of the 
agricultural industry is to be able provide for these changing consumer preferences. To maximize 
the availability of this protein, researchers are investigating ways to create a more efficient 
broiler. Several methods may be used to meet these demands including increasing production of 
broilers, increasing the growth rate of broilers, or increasing the amount of muscle found on each 
broiler. One approach to achieving increased growth rate or muscle accumulation is to modify 
myogenesis as the broiler embryo is developing.  
 Nicotinamide riboside (NR), a vitamin B3 analogue and NAD+ precursor, is one 
compound that has been shown to positively impact skeletal muscle qualities. When fed NR, 
NAD+ concentration in the skeletal muscle is significantly increased, which is important for 
energy production in the muscle (Canto et al., 2012; Frederick et al., 2016; Agerholm et al., 
2017; Fletcher et al., 2017).  Mitochondria biogenesis, is also increased with the addition of NR 
to the diet in mice (Khan et al., 2014). Due to the increase in mitochondria production, ATP 
levels are also amplified in the skeletal muscle of mice given NR (Khan et al., 2014; Ryu et al., 
2016; Frederick et al., 2016; Zhang et al., 2016). The changes observed in the muscle physiology 
may explain increases in muscle performance in studies performed by Canto et al. (2012), Ryu et 
al. (2016), and Zhang et al. (2016). 
 Along with the molecular changes observed after NR supplementation, muscle 
accumulation and conformation has been altered in some studies. Although NR did not increase 
overall muscle mass in healthy mice (Canto et al., 2012), increased in muscle growth as well as 
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an increase muscle fiber cross sectional area were demonstrated in mice with muscular dystrophy 
(Ryu et al., 2016). Zhang et al. (2016) detected an increase in number of muscle satellite cells 
after supplementation of NR, which could explain improvements to muscle repair seen in the 
muscular dystrophy model. 
 While supplementation of NR has been primarily through feed, one way to 
administer NR to developing broilers would be through in ovo injection. In ovo injection has 
previously been used to add compounds such as probiotics and vitamins (Bednarczyk et al., 
2016; Araujo et al., 2018), but no studies have examined the effect of in ovo injection of NR. 
Therefore, the objective of this study was to observe the effects of in ovo injection of 
nicotinamide riboside on whole-body growth measurements, NAD+ content, mitochondrial 
quantity, satellite cell number, and muscle characteristics in broilers. 
 METHODS 
 Egg Collection, Treatment Assignment, and Incubation 
 Fertilized broiler eggs (n=420) with an average weight of 65.6g (Cobb 500; Cobb 
Vantress, Siloam Springs, AR) were transported to Kansas State University (Manhattan, KS). 
Immediately following arrival, egg weights were recorded and eggs were ordered by weight. 
Within each 4 egg strata, eggs were randomly assigned to 1 of 4 treatments to be injected into the 
yolk of the egg at d 10 of incubation. Treatment consisted of 0, 2.5, 5, and 10mM NR made up in 
0.9% sterile saline that was to be injected into the yolk of the egg. Eggs were equally delegated 
to both NR treatment and day of processing, which included d15 of incubation, d19 of 
incubation, and day 21 or day of hatch. After designation of treatments, eggs were positioned 
with equal treatment representation onto trays and placed in an incubator (Sportsman 1502; GQF 
Manufacturing Company Inc., Savannah, A) with a setting of 37C and a relative humidity of  40 
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 2%. The incubator shelves rotated hourly to turn eggs and the trays were relocated daily 
throughout the incubator to account for variation. Tray weights were recorded daily to determine 
percent weight loss with a goal of 0.67% loss per day. 
 Solution Preparation and Injection Procedure 
The methods of the previous study were followed with some modifications. Briefly, 
solutions were prepared immediately prior to injection. To achieve a 1000mM, 500mM, and 
250mM solutions, 25.52g, 12.76g, and 6.38g of NR were added to 0.1L of autoclaved 0.9% 
sterile saline, respectively. To figure a final concentration in the egg, the average volume of the 
yolk from Cobb 500 eggs was determined to be 10mL. Injection with 100µl of the 1000, 500, or 
250mM NR solution into the 10mL yolk created the final concentration 2.5, 5, and 10mM NR. 
The control solution solely consisted of 0.9% sterile saline. All solutions were stored at room 
temperature before and during injection process. Candling verified the location of the yolk for 
injections and the injection site was cleansed with 70% ethanol. A 2.54-cm, 20-guage injection 
needle was used to create an opening in the shell and the needle was inserted approximately 1-
cm into injection site. Expulsion of 100l of assigned treatment took place in the yolk. A 1-cm2 
portion of medical tape (Nexcare; 3M, Maplewood, MN) was pressed over the opening. Treated 
broiler eggs were returned to the incubator under normal conditions until d 18 of incubation.    
The procedures of the previous study were followed with modifications. Briefly, at day 
15 of incubation, the assigned 120 eggs were removed from the incubator and the shells were 
penetrated at allow euthanasia with exposure to CO2 gas. After 25 minutes, embryos were 
removed from the eggs and were processed. Embryo weight, CR, head width, and head length 
were recorded. The ribs, pectoralis major, and pectoralis minor muscles were removed and kept 
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intact. This chest section was weighed, and the dimensions of length, width, and depth were also 
documented. Both the heart and liver were removed and weighed.  
After 18 d of incubation, relative humidity was increased to 60  2% and eggs were 
moved to hatching boxes. The processing procedures of d19 embryos and d21 hatched chicks 
were similar. The delegated 180 eggs for d19 embryo processing were removed from the 
incubator and exposed to prolonged CO2 gas and decapitation. As the remaining 120 eggs began 
to hatch on d21, chicks were marked by treatment and were placed into a heated environment 
under a lamp. All chicks were euthanized by prolonged exposure to CO2 gas and decapitation 
within 24h after hatch.  For both the d19 embryos and d21 chicks, overall weight, CR, head 
width, head length, head circumference, and chest circumference were documented. The 
embryos and chicks were sanitized with 70% ethanol and the skin was removed to expose the 
breast muscles and the overall chest width and length were measured using digital calipers 
(Traceable Digital Calipers; Fisher Scientific) Both the left and right PM muscles were removed 
with a scalpel. The left PM weight and the dimensions of this muscle, including PM length, 
width, and depth, were recorded. The left PM was placed onto a tongue depressor and moved to 
a -80C freezer for storage until use for histological sectioning. The right PM was also stored for 
further analyses. The left leg was removed caudal to the hip joint and the rectus femoris, vastus 
lateralis, vastus intermedius, and vastus medialis still attached to the femur, were blotted on 
paper to measure the approximate area of the leg. The heart and liver were removed for organ 
weights. 
 Histology and Immunohistochemistry 
The methods of the previous study were followed with modifications. The left PM was 
embedded into tissue embedding media (Fisher Scientific, Pittsburg, PA), cooled with liquid 
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nitrogen, and stored in a -80C until further histological analysis. When sectioned, cuts were 
made perpendicular to the length of the PM muscle. To analyze muscle fiber size and satellite 
cell number via immunohistochemistry, six cryosections were cut (10M thick) and positioned 
onto positively charged slides (Diamond White Glass; Globe Scientific Inc., Paramus, NJ). One 
additional slide per sample with six cryosections (20M thick) were obtained for  SDH staining.  
The methods of Noel et al. (2016) were followed for fiber and satellite cell 
immunohistochemistry with modifications. Briefly, cryosections were incubated in a 5% horse 
serum and 0.2% TritonX-100 in PBS blocking solution for 30 minutes and then for 1h at room 
temperature in a primary antibody solution. The primary antibody solution consisted of 1:2 
blocking solution, 1:2 Pax7 antibody (Developmental Studies Hybridoma Bank), and 1:500 -
dystrophin (Thermo Scientific, Waltham, MA). Cryosections were washed with PBS 3 times for 
5 minutes and then incubated again 30 minutes with blocking solution containing 1:1,000 Alexa-
Flour 594 goat-anti-rabbit heavy and light chains (Life Technologies), 1:1,000 Hoescht Dye 
33342 (Life technologies), and 1:1000 Alexa-Flour 488 goat-anti-mouse IgG1 (Life 
Technologies). Cryosections were washed again as stated previously. Every two sections 
received 5l of 9:1 glycerol in PBS and coverslips were added and affixed with clear fingernail 
polish.  
Succinate dehydrogenase staining methods from Noel et al. (2016) were followed. Slides 
containing six cryosections were incubated in a pre-warmed solution containing a nitro-blue 
tetrazolium solution, phosphate buffer, and a sodium succinate solution for 1h at 37C. After 
incubation, slides were washed in Milli-Q (MQ) water 3 times each for 5 minutes. A 9:1 glycerol 
in PBS solution was placed on every two cryosections and slides were cover-slipped for imaging. 
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All cryosections were imaged at 20X magnification using a Nikon Elipse TI-U inverted 
microscope (Nikon Instruments Inc., Melville, NY). A Nikon DS-QiMC digital camera (Nikon 
Instruments Inc.) was used to photograph sections for muscle fiber CSA and satellite cell 
number. Photomicrographs for SDH were taken using a Nikon DS-Fil color digital camera 
(Nikon Instruments Inc.). An average of 1000 fibers were analyzed using NIS-Elements Imaging 
software (Basic Research, 3.3; Nikon Instruments Inc.) to determine fiber CSA for each sample 
and the corresponding area was analyzed for satellite cell number. An average of 50 skeletal 
muscle bundles was analyzed for SDH mean intensity on the same software. The scale for mean 
intensity starts with a value of 0, which indicates black or the most intense staining, to a value of 
250, which signifies white or the least intense staining. (Satellite cell number and succinate 
dehydrogenase staining data not presented). 
 
 Mitochondrial Quantification 
Mitochondrial extraction and western blotting was used to quantify mitochondrial 
cytochrome C. The extraction procedure of Smith et al. (1967) was as follows with 
modifications. Briefly, leg muscle tissue was powdered and a maintenance buffer containing 
sucrose, mannitol, HEPES, and K2PO4 was added before homogenization. Homogenized sample 
was filtered with double layer cheesecloth and spun at 650  g for 10 minutes at 4C. 
Supernatant was strained with the cheesecloth. The centrifugation and straining steps were 
completed one additional time. The collection of supernatant was spun at 7750  g for 25 
minutes at 4C. The resulting supernatant was decanted and the pellet was washed three times in 
maintenance buffer. The cleaned pellet was suspended in maintenance buffer and stored at -80C 
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for subsequent western blot analysis. Protein concentrations were determined using a Pierce 
BCA Assay Kit (Thermo Scientific Rockford, IL). 
The western blot method of Phelps et al. (2016) was followed with modifications. 
Proteins were separated via electrophoresis on 7.5% polyacrylamide gels and transferred to 
nitrocellulose membranes (88018; Thermo Scientific) using a TE77X Semi-dry Transfer Unit 
(Hoefer Inc., Holliston, MA). Blots were blocked with 5% nonfat dry milk in TBS-T for 30 
minutes and then incubated overnight with a 1:1000 Cytochrome C mouse monoclonal antibody 
(Santa Cruz Biotechnology Inc., Dallas, TX). Blots were washed with TBS-T 3 times for 5 
minutes each and then incubated in, IgG HRP-linked secondary an,tibody (7076; Cell Signaling 
Technology, Danvers, MA) for 1 h. Blots were washed as mentioned above and enhanced with 
chemiluminescence.  A ChemiDoc-It 415 Imaging System (UVP LLC; Upland, CA) was used to 
image blots and band intensities were analyzed using VisionWorksLS Image Acquisition and 
Analysis Software (UVP, LLC). (Mitochondrial Cytochrome C data not presented). 
 
 NAD+ Quantification 
The methods of the previous study were followed to quantify levels of NAD+ with a 
NAD+/NADH Assay Kit (Abnova, Taiwan).  Two samples were equally pooled from the same 
treatment to reach a weight of 50mg of muscle tissue. The combined samples were homogenized 
in 100l of NAD extraction buffer and heated at 60C for 5 minutes. Assay buffer and the 
opposing NADH extraction buffer were added, samples were vortexed and centrifuged at 17,500 
x g for 5 minutes. The supernatants were extracted and aliquoted along with the working reagent, 
and the absorbance was measured at 565nm at time points 0 and 15 minutes using a 
spectrophotometer (BioTek, Winooski, VT, USA).  To calculate the NAD+ concentration, using 
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the change in optical density (OD) from 0 minutes to 15 minutes and dividing by the slope of the 
NAD+ standard curve. (NAD+ data not presented). 
 
 Cyclin Quantification 
Cyclin D1, D2, and D3 were quantified utilizing the methods of Barnett et al. (2016) 
using Real Time (RT) polymerase chain reaction (PCR). Briefly, 50mg of the quadriceps muscle 
was homogenized in 3ml of Trizol. Samples were incubated at room temperature for 20 minutes, 
600µl of chloroform was added, and was centrifuged at 3220 x g for 1h. The remaining top, 
aqueous layer was moved to a new conical tube and an equal amount of Isopropanol was added, 
then incubated at room temperature for 30 minutes.  The sample was centrifuged again as 
specified previously and the supernatant was discarded. The pellet was washed with 75% 
ethanol. For RNA extraction, a PureLink RNA Mini Kit was used (12183018A; Thermo 
Scientific). The previous pellet was resuspended in 600µl of the kit lysis buffer, 600µl of 70% 
ethanol was added, and then the sample was vortexed. The mixture was aliquoted to a spin 
cartridge and centrifuged at 12,000 x g for 30 seconds. The flow though was discarded, 650µl of 
Was Buffer I was added to the cartridge, and centrifuged at the same settings as the previous 
spin. The flow through was discarded and 80µl of PureLink DNase was added to the cartridge. 
After an incubation for 15 minutes at room temperature, 650µl of Wash Buffer I was added and 
centrifuged as before. The flow through was discarded and 500µl of Wash Buffer II was 
aliquoted to the cartridge placed in a recovery tube. Centrifugation was at 12,000 x g for 1 
minute. After the addition of 30µl of RNase Free Water and an incubation of 1 minute at room 
temperature, samples were centrifuged at 12,000 x g for 2 minutes. The liquid in the collection 
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tube was kept and heated at 65ºC and the RNA concentration was determined on the NanoDrop 
(Thermo Scientific). 
A RT reaction was used to synthesize cDNA. Each sample was calculated to run a 50ng 
reaction. Each sample was brought up to 8µl with sterile filtered water. One microliter of both 
DNase enzyme and DNase Buffer was added for a total volume of 10µl. The sample was ran for 
30 minutes at 37ºC. A volume of 1µl of DNase Stop Solution was added and the stop step was 
run at 65ºC for 10 minutes. A master mix was created containing 10X RT Buffer, 25X dNTP 
mix, 10X primer, Multiscribe Reverse Transcriptase, RNase inhibitor, and sterile filtered water. 
Nine microliters of the master mix were added to each sample. Each sample was ran for the RT 
reaction utilized the flowing cycle: 25ºC for 10 minutes, 37ºC for 120 minutes, 85ºC for 5 
seconds, and held at 4ºC.  
The RT PCR reaction utilized a standard curve with 8 standards. This was created by 
pooling 30µl of each cDNA sample to create standard one, and was diluted 4-fold until there 
were 8 total standards. To run each sample, 20µl of the RT reaction was diluted 1:16 for all three 
cyclins. A SYBR Green master mix was created with SYBR green, forward primer, reverse 
primer, and water, and 10µl of this mix was added to each sample. The PCR used the following 
thermocycle: 50ºC for 2 minutes, 50ºC for 10 minutes, 95ºC for 10 minutes, and 95ºC for 15 
seconds. The cyclins were measured by the amount of DNA fluoresced. (Cyclin D quantification 
data not presented). 
 Statistics 
Data were analyzed as a completely randomized design with egg as the experimental unit. 
All models were analyzed using the MIXED procedure of SAS 9.4 (SAS Inst. Inc., Cary, NC) 
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with treatment (TRT) and injection location (LOC) as fixed effects. Statistical significance was 
set at P  0.05. 
 RESULTS 
 Body Morphometrics 
There was no treatment effect on d15 embryos for all body measures (P ≥ 0.23; Table 
4.1). Treatment did not affect all whole body measures (P ≥ 0.08; Table 4.2) for d19 embryos 
with the exception of head circumference, where the 5.0 and 10.0mM NR concentrations were 
larger (P < 0.05) compared to the saline control. Embryos injected with 2.5mM NR had smaller 
head circumferences (P < 0.04) than the 10.0mM embryos, but were similar to all other 
treatments (P ≥ 0.07). There was no treatment effect on all d21 chick body measurements (P ≥ 
0.08; Table 4.2); though injection of 2.5mM NR increased both head length and chest width (P ≤ 
0.03) compared to the saline and 10.0mM chicks. Head length and chest width from hatched 
chicks injected with 5.0mM NR was similar (P ≥ 0.10) to all other treatments. Treatment did not 
affect leg blot area of hatched chicks (P = 0.84; Figure 4.3). 
There was no treatment effect on all chest plate measurements (P > 0.22; Table 4.3). For 
d19 embryos, treatment with NR at every level increased both PM weight and length (P < 0.01), 
which were not different from each other (P ≥ 0.25). Nicotinamide riboside treatment did not 
affect PM width or depth (P ≥ 0.12). Nicotinamide riboside treatment did affect all PM measures 
taken from hatched chicks (P ≤ 0.02). Both PM weight and width were increased by injection of 
NR at all three concentrations (P < 0.01), which did not differ from each other (P ≥ 0.44). 
Hatched chicks injected with 2.5 and 5.0mM NR had longer PM measurements (P ≤ 0.01) than 
the saline treatment, while the 10.0mM concentration group was similar to all other treatments (P 
≥ 0.06). Injection of 5.0mM NR increased the depth of the PM (P ≤ 0.04) from d21 chicks 
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compared to both the saline and 10mM treatments, although the 2.5mM NR group had similar 
PM depth (P ≥ 0.06) to all other injection treatments.  
 Muscle Fiber Characteristics 
There was no treatment effect on muscle fiber cross sectional area (P = 0.20; Figure 4.1). 
Treatment with NR did affect fiber number per 1000µm (P < 0.01: Figure 4.2). The addition of 
2.5 and 5mM NR increased fiber number (P ≤ 0.01) compared to the control, while injection of 
10mM NR showed to largest increase in fiber number compared to all other treatments (P < 
0.01).  
 Additional Results 
At the time of publication for this thesis, satellite cell number, succinate dehydrogenase 
stain fiber oxidation, mitochondrial quantity, NAD+ quantity, and Cyclin D expression were 
proprietary. These data sets are expected to be published in a peer reviewed journal at a later 
date. 
 DISCUSSION 
 Body Morphometrics 
 Over the last 60 years, demand for chicken has increased dramatically with yearly per 
capita consumption rising by 70 lbs. (USDA, 2018). Due to these changing consumer 
preferences, scientists are investigating ways to capitalize on poultry growth rates. In the past, in 
ovo injected growth hormone increased overall body weight of broilers (Hargis et al., 1989). In 
recent times, consumers do not look favorably at the use of growth hormones, making meat 
animal producers move away from these practices. Due to these consumer demands, some 
studies have observed the effects of injecting compounds that are more widely accepted. In ovo 
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injection with selenium, probiotics, and vitamin E did not affect body weight unlike injected 
growth hormone (Macalintal et al., 2012; Bednarczyk et al., 2016; Araujo et al., 2018).  
No previous studies have tested the effects of nicotinamide riboside on improving the rate of 
growth in meat producing animals; however, several studies have looked at the effect of NR on 
whole body measurements and skeletal muscle in rodents. Studies by Canto et al. (2012) and 
Ryu et al. (2016) fed NR to mice and reported no change in overall weight after supplementation. 
In contrast, one study did demonstrate a decrease in overall weight gain, but only when mice 
were fed a high-fat diet with the addition of NR (Canto et al., 2012). In experiment one, neither 
injection of NR into the yolk or the albumin led to an increase in overall weight and other body 
morphometrics. The current study, experiment two, focused on broiler growth, in which in ovo 
injection of NR at several concentrations did not affect overall body weight in d 15 embryos, d 
19 embryos, or hatched chicks. The unaffected body weight between treatments was supported 
by no changes in all other body measurements for d 15 embryos. Similarly, most body 
measurements were unaffected by treatment with the exception of a slight increase in head 
circumference for d 19 embryos as injection concentration increased, as well as increased head 
lengths and chest widths with the injection on 2.5mM NR in hatched chicks. Overall, the lack of 
significance on overall body weight of the current study are similar to literature regarding in ovo 
injection studies of other vitamins, minerals, and probiotics. Similarly, supplementation studies 
utilizing NR are in agreement with the current study; under normal conditions, NR does not lead 
to a change in body weight. 
 As seen with overall body weight, only in ovo injection with growth hormone 
successfully increased the breast muscle weight (Hargis et al., 1989), compared to other more 
consumer accepted compounds such as a vitamin E injection, which did not affect skeletal 
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muscle growth (Araujo et al., 2018).  While NR has only previously been injected into broiler 
eggs, with the exception of experiment one, NR feed supplementation in rodents has resulted in 
varied effects across many studies. One study reported that healthy mice fed NR had similar lean 
muscle mass compared to mice not supplemented with NR (Canto et al., 2012). In contrast, NR 
demonstrated an increase in skeletal muscle mass in mice, but only under unusual circumstances. 
In two separate studies, NAMPT knockout mice and muscular dystrophy mice had lower muscle 
mass compared to normal mice, but showed improvements to skeletal muscle resulting in muscle 
mass similar to control mice with the addition to NR (Frederick et al., 2016; Ryu et al., 2016). In 
experiment one, injection of NR into the yolk of the egg led to a 35% increase in PM weight and 
injection of NR into both the yolk and the albumin increased PM length by an average of 14%. 
In the current study, injection of NR into the yolk of the egg had no effect on PM weight or 
dimensions from d 15 broiler embryos. However, at d 19 and day of hatch, injection of NR has 
positive effects on PM muscle development. In ovo injection of NR increased PM weight by an 
average of 24% and lengthened the PM by an average of 16% for d 19 embryos compared to the 
saline control. Even larger changes to the PM were observed from NR chicks at hatch, including 
an increase in weight by 33%, length by 16%, width by 18%, and depth by 20%. These differing 
results among past studies may be due to the prenatal method at which NR was delivered to 
broiler eggs, whereas in past studies NR was given as a feed supplementation in mice 
postnatally. However, the results observed between experiment one and two are similar, whereas 
NR injection increased breast muscle growth after d 15 of incubation. 
Muscle Fiber Characteristics 
In past studies, muscle fiber CSA after supplementation with NR has only been inspected 
in mice models in the situation of NAMPT knockout and muscular dystrophy. In both cases, 
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increases in muscle fiber CSA were reported with the addition of NR in the diet (Frederick et al., 
2016; Ryu et al., 2016). The current study demonstrated conflicting results with past literature, 
with no changes in fiber size observed after an injection of NR into either the yolk of albumin of 
the egg at d 10 of incubation. In contrast to past literature, but in similarity to experiment one, no 
differences in PM muscle fiber CSA were detected between treatments. These findings would 
indicate that the overall growth of the PM observed was not due to decrease in size of muscle 
fibers. For growth to occur without the increase in fiber size, muscle fiber number must be 
altered. In experiment one, an increase in fiber number was observed by injection of 2.5mM NR 
into the yolk of the egg by 37.9%. Similarly, for the current study, muscle fiber number per 
1000m2 was significantly larger than the control chicks for all NR concentration treatments. 
Fiber number was increased by an average of 30% for the 2.5 and 5mM treatments and by 70% 
for the 10mM injection. No past studies concerning either in ovo injections of NR evaluated 
muscle fiber number.  In past literature, NR was given postnatally so fiber number could not be 
altered in previous rodent studies.  In the current study, NR was injected prenatally so that 
embryonic myogenesis may have been affected. While fiber size was not altered by NR injection 
of any concentration, fiber number was significantly increased by all three levels of NR, with 
10mM leading to the largest number of skeletal muscle fibers. Overall, the current study’s 
findings were not comparable to past literature, however were similar to the results of 
experiment one. This may largely be due to the differences in species and the method and time at 
which NR was given. 
 CONCLUSSION 
Injection of nicotinamide riboside at d 10 in incubation into both the yolk of developing 
broiler eggs did not affect most measures of body growth; however, injection did positively 
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affect many skeletal muscle aspects. The three differing levels of NR did not affect any overall 
body measures for d 15 embryos, and similarly had no effects on most body measures for d 19 
embryos and d 21 hatched chicks. Conversely, many skeletal muscle properties from the 
pectoralis major were altered. Injection of NR did positively affect some PM measures for d 19 
embryos, but by d 21, all PM dimensions were increased. Pectoralis major development peaked 
with the 5mM NR concentration. In the PM of hatched chicks, muscle fiber size remained the 
same, while muscle fiber number increased with increasing NR concentration treatments.  
These findings indicate that while body measurements were mostly unchanged for all 
time points, positive transformations were made to PM characteristics with an NR injection into 
the yolk. For most qualities, maximum effects were seen at the 5mM NR injection level, with the 
exception of the largest muscle fiber number per 1000 square microns from the 10mM. Overall, 
the new injection technology may be a solution to improving growth rate in broilers and could be 
utilized to meet the ever growing consumer demand for chicken. 
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 Nicotinamide Riboside dose, mM  
Item 0.0 2.5 5.0 10.0  SEM TRT1 
Chick weight, g  13.61 14.46 14.18 13.94  0.86 0.90 
Body 
measurements, mm 
       
Crown-rump length 59.40 61.40 61.07 61.05  1.50 0.75 
Head width 13.62 13.70 13.72 14.02  0.28 0.73 
Head length 17.06 17.63 17.78 17.41  0.86 0.93 
Heart weight, g 0.13 0.14 0.13 0.15  0.01 0.23 
Liver weight, g 0.27 0.27 0.25 0.28  0.02 0.68 
abc of treatment within row differs (P < 0.05). 
1TRT = treatment of 0.0, 2.5, 5.0, and 10.0mM NR in 0.9% sterile saline 
 
 
Table 4.1 Whole body measurements from d15 broiler embryos injected with 0, 2.5, 5, or 10mM Nicotinamide Riboside (NR) at day 
10 of incubation 
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Table 4.2 Whole body measurements from d19 embryos and d21 hatched chicks injected with 0, 2.5, 5, and 10mM Nicotinamide 
Riboside (NR) at d10 of incubation 
 Nicotinamide Riboside dose, mM  
Item 0.0 2.5 5.0 10.0  SEM TRT1 
D19 embryo        
Weight, g  37.93….... 37.74 37.89 38.06  1.42 0.99 
Body measurements, mm        
Crown-rump length 84.95 84.34 85.87 86.32  0.62 0.08 
Head width 16.95 15.38 15.31 15.40  0.76 0.34 
Head length 17.78 17.67 17.43 17.58  0.17 0.49 
Head circumference  52.96 a 53.17 a,b 54.79 b,c 54.97 c  0.06 0.04 
Chest width 15.56 15.49 16.32 15.44  0.29 0.14 
Chest length 18.34 18.60 18.45 18.29  0.31 0.89 
Chest circumference 57.04 59.47 60.07 61.52  0.13 0.08 
Heart weight, g 0.22 0.22 0.22 0.23  0.01 0.56 
Liver weight, g 0.63 0.64 0.64 0.63  0.02 0.98 
D21 chick        
Weight, g 45.30 46.91 46.13 46.60  0.81 0.16 
Body measurements, mm        
Crown-rump length 93.24 95.44 95.08 93.01  1.04 0.16 
Head width 15.56 15.53 15.64 15.48  0.21 0.83 
Head Length 17.76 a 18.66 b 18.22 a,b 17.76 a  0.29 0.05 
Head circumference 54.71 55.73 55.57 53.94  0.1 0.17 
Chest width 15.90 a 17.07 b 16.56 a,b 16.14 a  0.29 <0.05 
Chest length 20.47 21.90 21.18 21.11  0.62 0.14 
Chest circumference 60.88 61.18 62.47 61.39  0.11 0.42 
Heart weight, g 0.29 0.31 0.31 0.32  0.01 0.08 
Liver weight, g 0.88 0.84 0.90 0.96  0.05 0.28 
abc of treatment within row differs (P < 0.05). 







 Nicotinamide Riboside dose, mM  
Item 0.0 2.5 5.0 10.0  SEM TRT1 
2D15 Chest plate measurements        
Weight, g 0.73 0.81 0.82 0.84  0.06 0.60 
Length, mm 17.60 18.25 17.79 18.50  0.71 0.77 
Width, mm 13.73 14.65 15.18 14.86  0.54 0.22 
Depth, mm 6.93 7.20 7.07 6.61  0.25 0.34 
D19 Pectoralis major measurements        
Weight, g 0.14a 0.17b 0.18b 0.17b  0.01 <0.01 
Length, mm 15.12a 17.23b 17.72b 17.65b  0.38. <0.01 
Width, mm  5.11 5.48 5.66 5.57  0.17 0.12 
Depth, mm 2.68 2.91 2.73 2.87  0.10 0.29 
D21 Pectoralis major measurements        
Weight, g 0.17a 0.23b 0.23b 0.22b  0.02 <0.01 
Length, mm 17.61a 19.89b 20.33b 19.13a,b  0.70. <0.01 
Width, mm 4.63a 5.50 b 5.56 b 5.39b  0.30 <0.01 
Depth, mm 2.78a 3.14a,b 3.33 b 2.97a  0.15 0.02 
abc of treatment within row differs (P < 0.05). 
1TRT = treatment of 0.0, 2.5, 5.0, and 10.0mM NR in 0.9% sterile saline. 
2 Chest plate includes the ribs, pectoralis major, and pectoralis minor muscles. 
 
 
Table 4.3 Overall chest and Pectoralis major muscle measurements from d15 embryos, d19 embryos, and d21 hatched broiler 
chicks injected with 0, 2.5, 5, or 10mM Nicotinamide Riboside (NR) at day 10 of incubation 
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Figure 4.1 Muscle fiber cross-sectional area (CSA) from the pectoralis major of hatched broiler 
chicks injected with 0, 2.5, 5, or 10 mM Nicotinamide Riboside (NR) in 0.9% sterile saline into 
the yolk of fertilized broiler eggs at day 10 of incubation. The PM muscle was embedded in a 
sectioning compound, sectioned onto a slide, and stained with Dystrophin antibody (Thermo 
Scientific). For each sample, the area of 1000 fibers were analyzed on the NIS-Elements Imaging 

























































Figure 4.2 Muscle fiber number per 1000 square microns from the pectoralis major of hatched 
broiler chicks injected with 0, 2.5, 5, or 10 mM Nicotinamide Riboside (NR) in 0.9% sterile 
saline into the yolk of fertilized broiler eggs at day 10 of incubation. The PM muscle was 
embedded in a sectioning compound, sectioned onto a slide, and stained with Dystrophin 
antibody (Thermo Scientific). For each sample, fiber number was analyzed on the NIS-Elements 




Figure 4.4 Effect of Nicotinamide Riboside (NR) concentration injected into fertilized broiler 
eggs at d 10 of incubation on leg blot area. The left leg was removed caudal to the hip joint and 
the rectus femoris, vastus lateralis, vastus intermedius, and vastus medialis still attached to the 
femur, were blotted on paper to measure the approximate area of the leg. The resulting space was 
traced, and the area was analyzed with NIS-Elements Imaging software (Basic Research, 3.3; 
Nikon Instruments Inc.). 
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Appendix A - Representative pictomicrograph of broiler chick 
skeletal muscle fibers from the Pectoralis major 
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